Amphotericin B nebulization to prevent invasive pulmonary fungal infections during artificial liver therapy

Phase 4, open-label trial of amphotericin b in hepatic disease and invasive pulmonary fungal disease (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoints: Proportion of pulmonary fungal infections after initiation of artificial liver therapy, Peripheral blood TBNK cell counts and 8 more. Planned start Dec 2024; status: not yet recruiting.